These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 9632368

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
    Sall DJ, Arfsten AE, Bastian JA, Denney ML, Harms CS, McCowan JR, Morin JM, Rose JW, Scarborough RM, Smyth MS, Um SL, Utterback BG, Vasileff RT, Wikel JH, Wyss VL, Jakubowski JA.
    J Med Chem; 1997 Aug 29; 40(18):2843-57. PubMed ID: 9288166
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K, Shimazaki T, Aoki Y, Yamashita H, Tanaka E, Banba S, Yazawa K, Kibayashi K, Banno H.
    J Med Chem; 1998 Oct 08; 41(21):4036-52. PubMed ID: 9767641
    [Abstract] [Full Text] [Related]

  • 5. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH, Cook JJ, Brashear KM, Breslin MJ, Glass JD, Gould RJ, Halczenko W, Holahan MA, Lynch RJ, Sitko GR, Stranieri MT, Hartman GD.
    J Med Chem; 1996 Nov 08; 39(23):4583-91. PubMed ID: 8917647
    [Abstract] [Full Text] [Related]

  • 6. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
    Su T, Naughton MA, Smyth MS, Rose JW, Arfsten AE, McCowan JR, Jakubowski JA, Wyss VL, Ruterbories KJ, Sall DJ, Scarborough RM.
    J Med Chem; 1997 Dec 19; 40(26):4308-18. PubMed ID: 9435900
    [Abstract] [Full Text] [Related]

  • 7. Design of a new class of orally active fibrinogen receptor antagonists.
    Klein SI, Molino BF, Czekaj M, Gardner CJ, Chu V, Brown K, Sabatino RD, Bostwick JS, Kasiewski C, Bentley R, Windisch V, Perrone M, Dunwiddie CT, Leadley RJ.
    J Med Chem; 1998 Jul 02; 41(14):2492-502. PubMed ID: 9651154
    [Abstract] [Full Text] [Related]

  • 8. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, Müller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Müller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B.
    J Med Chem; 1996 Aug 02; 39(16):3139-47. PubMed ID: 8759635
    [Abstract] [Full Text] [Related]

  • 9. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
    Ishikawa M, Kubota D, Yamamoto M, Kuroda C, Iguchi M, Koyanagi A, Murakami S, Ajito K.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2109-30. PubMed ID: 16309912
    [Abstract] [Full Text] [Related]

  • 10. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM, Heath JA, Smyth MS, Pandey A, Rose JW, Seroogy JM, Volkots DL, Nannizzi-Alaimo L, Park GL, Lambing JL, Hollenbach SJ, Scarborough RM.
    J Med Chem; 2004 Apr 08; 47(8):2037-61. PubMed ID: 15056002
    [Abstract] [Full Text] [Related]

  • 11. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
    Kubota D, Ishikawa M, Yamamoto M, Murakami S, Hachisu M, Katano K, Ajito K.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2089-108. PubMed ID: 16309911
    [Abstract] [Full Text] [Related]

  • 12. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
    Sugihara H, Fukushi H, Miyawaki T, Imai Y, Terashita Z, Kawamura M, Fujisawa Y, Kita S.
    J Med Chem; 1998 Feb 12; 41(4):489-502. PubMed ID: 9484499
    [Abstract] [Full Text] [Related]

  • 13. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
    Ishikawa M, Hiraiwa Y, Kubota D, Tsushima M, Watanabe T, Murakami S, Ouchi S, Ajito K.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2131-50. PubMed ID: 16307881
    [Abstract] [Full Text] [Related]

  • 14. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P, Badorc A, Lalé A, Bordes MF, Bornia J, Labouret C, Bernat A, de Cointet P, Hoffmann P, Maffrand JP, Herbert JM.
    Thromb Haemost; 1998 Sep 01; 80(3):469-76. PubMed ID: 9759629
    [Abstract] [Full Text] [Related]

  • 15. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ, Cox D, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2000 Nov 01; 295(2):670-6. PubMed ID: 11046104
    [Abstract] [Full Text] [Related]

  • 16. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
    Olson RE, Sielecki TM, Wityak J, Pinto DJ, Batt DG, Frietze WE, Liu J, Tobin AE, Orwat MJ, Di Meo SV, Houghton GC, Lalka GK, Mousa SA, Racanelli AL, Hausner EA, Kapil RP, Rabel SR, Thoolen MJ, Reilly TM, Anderson PS, Wexler RR.
    J Med Chem; 1999 Apr 08; 42(7):1178-92. PubMed ID: 10197962
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of novel biologically active thrombin receptor non-peptide mimetics based on the pharmacophoric cluster Phe/Arg/NH2 of the Ser42-Phe-Leu-Leu-Arg46 motif sequence: platelet aggregation and relaxant activities.
    Alexopoulos K, Fatseas P, Melissari E, Vlahakos D, Roumelioti P, Mavromoustakos T, Mihailescu S, Paredes-Carbajal MC, Mascher D, Matsoukas J.
    J Med Chem; 2004 Jun 17; 47(13):3338-52. PubMed ID: 15189031
    [Abstract] [Full Text] [Related]

  • 18. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
    Xue CB, Wityak J, Sielecki TM, Pinto DJ, Batt DG, Cain GA, Sworin M, Rockwell AL, Roderick JJ, Wang S, Orwat MJ, Frietze WE, Bostrom LL, Liu J, Higley CA, Rankin FW, Tobin AE, Emmett G, Lalka GK, Sze JY, Di Meo SV, Mousa SA, Thoolen MJ, Racanelli AL, Olson RE.
    J Med Chem; 1997 Jun 20; 40(13):2064-84. PubMed ID: 9207948
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity.
    Wang WY, Hsieh PW, Wu YC, Wu CC.
    Biochem Pharmacol; 2007 Aug 15; 74(4):601-11. PubMed ID: 17601492
    [Abstract] [Full Text] [Related]

  • 20. Antiplatelet efficacy of XV459, a novel nonpeptide platelet GPIIb/IIIa antagonist: comparative platelet binding profiles with c7E3.
    Mousa SA, Bozarth JM, Lorelli W, Forsythe MS, Thoolen MJ, Slee AM, Reilly TM, Friedman PA.
    J Pharmacol Exp Ther; 1998 Sep 15; 286(3):1277-84. PubMed ID: 9732389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.